Literature DB >> 17041464

Bronchiolitis obliterans with organizing pneumonia associated with scleroderma and scleroderma spectrum diseases.

J Grant Taylor1, Marcy B Bolster.   

Abstract

Systemic sclerosis (SSc) is an autoimmune disorder with a high mortality rate from pulmonary manifestations, such as interstitial lung disease and pulmonary hypertension, seen at autopsy in 90% and 75% of patients, respectively. Bronchiolitis obliterans with organizing pneumonia (BOOP) has numerous causes, but it has only been reported in three patients with SSc. We present three cases of biopsy-proven BOOP in patients with scleroderma spectrum disease, including diffuse cutaneous SSc, mixed connective tissue disease with SSc features, and limited cutaneous SSc that later evolved to dermatomyositis/SSc overlap. BOOP and SSc alveolitis have similar findings on spirometry, radiographs, and BAL; the definitive diagnosis of BOOP was therefore made by open lung biopsy. Cyclophosphamide is the current treatment of alveolitis associated with SSc, whereas high-dose prednisone is used to treat BOOP. As a result of this difference, we emphasize the importance of a thorough investigation of pulmonary disease in SSc patients to exclude BOOP and treat appropriately.

Entities:  

Year:  2003        PMID: 17041464     DOI: 10.1097/01.rhu.0000083860.27509.f1

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  6 in total

Review 1.  Bronchiolitis obliterans organizing pneumonia in patients with autoimmune rheumatic diseases.

Authors:  Carmen Maria Lara Rojas; Elisabetta Borella; Lavinia Palma; Silvio Ragozzino; Enrique De Ramón; Ricardo Gomez-Huelgas; Leonardo Punzi; Andrea Doria
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

Review 2.  Tomography patterns of lung disease in systemic sclerosis.

Authors:  Andréa de Lima Bastos; Ricardo de Amorim Corrêa; Gilda Aparecida Ferreira
Journal:  Radiol Bras       Date:  2016 Sep-Oct

3.  PET/CT and inflammatory mediators in systemic sclerosis-associated interstitial lung disease.

Authors:  Andréa L Bastos; Gilda A Ferreira; Marcelo Mamede; Eliane V Mancuzo; Mauro M Teixeira; Flávia P S T Santos; Cid S Ferreira; Ricardo A Correa
Journal:  J Bras Pneumol       Date:  2022-06-06       Impact factor: 2.800

4.  Chest CT imaging features for prediction of treatment response in cryptogenic and connective tissue disease-related organizing pneumonia.

Authors:  Young Hoon Cho; Eun Jin Chae; Jin Woo Song; Kyung-Hyun Do; Se Jin Jang
Journal:  Eur Radiol       Date:  2020-02-10       Impact factor: 5.315

Review 5.  Pictorial review of intrathoracic manifestations of progressive systemic sclerosis.

Authors:  Hamdan Al-Jahdali; Prabhakar Rajiah; Carolyn Allen; Shyam Sunder Koteyar; Ali Nawaz Khan
Journal:  Ann Thorac Med       Date:  2014-10       Impact factor: 2.219

6.  Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.

Authors:  Padmanabha D Shenoy; Manish Bavaliya; Sujith Sashidharan; Kaveri Nalianda; Sreelakshmi Sreenath
Journal:  Arthritis Res Ther       Date:  2016-06-02       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.